Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib for Chronic Graft vs. Host Disease
NCT02491359Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2015
- Primary completion
- Feb 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in chronic graft-versus-host disease (cGVHD), sponsored by Fred Hutchinson Cancer Center. Started Nov 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02491359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491359.